Unknown

Dataset Information

0

Biological therapy for ulcerative colitis.


ABSTRACT: Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD) worldwide. Better understanding of the pathogenesis of UC has led to the development of novel therapeutic agents that target specific mediators of the inflammatory cascade. A number of biological agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of UC and several more are currently in various phases of drug development. The commonly used agents include TNF? antagonists (e.g. infliximab, adalimumab, and golimumab) and anti-integrin agents (vedolizumab). These biological agents have profoundly influenced the management of UC patients, especially those with refractory disease. This paper reviews the currently available knowledge and evidence for the use of various biological agents in the treatment of UC.

SUBMITTER: Arora Z 

PROVIDER: S-EPMC4423460 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Biological therapy for ulcerative colitis.

Arora Zubin Z   Shen Bo B  

Gastroenterology report 20141024 2


Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD) worldwide. Better understanding of the pathogenesis of UC has led to the development of novel therapeutic agents that target specific mediators of the inflammatory cascade. A number of biological agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of UC and several more are currently in various phases of drug development. The commonly used agents include TNFα antagonists (e.g. infli  ...[more]

Similar Datasets

| S-EPMC6244035 | biostudies-other
2022-12-17 | GSE220815 | GEO
| S-EPMC8086577 | biostudies-literature
| S-EPMC6487890 | biostudies-literature
| S-EPMC1127254 | biostudies-literature
| S-EPMC9955668 | biostudies-literature
| S-EPMC3480540 | biostudies-literature
| PRJNA420680 | ENA
| PRJEB31884 | ENA
2018-04-01 | GSE107597 | GEO